TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16674614
Drug: Nasopharyngeal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasopharyngeal oxygen insufflation at a flow of 5 l.min(‐1)
Study: 14571613
Drug: Kangxin capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangxin capsule (KXC)
Study: 11089449
Drug: Hydrocortisone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (40 mg, p.o.)
Study: 1456568
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy (controlled nutritional support)
Study: 31337298
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with successful reperfusion
Study: 24758079
Drug: Busheng Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busheng Huoxue Capsule (BHC) plus caltrate-D (600 mg CaCO3)
Study: 24758079
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg per week) plus caltrate-D
Study: 23106761
Drug: Modified Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Cognitive Processing Therapy (MCPT)
Study: 20124230
Drug: Extended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended therapy (Nicoderm CQ, 21 mg, for 24 weeks)
Study: 12542901
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of cefepime (4-g continuous infusion over 24 h for 48 h)
Study: 12542901
Drug: Intermittent injection
Normalized name: Jelco Intermittent Injection Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent injection of cefepime (2-g bolus every 12 h for 48 h)
Study: 8873689
Drug: Bumetanide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (single intravenous bolus dose, doses ranged from 0.005 to 0.100 mg/kg)
Study: 8873689
Drug: Bumetanide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (single intravenous bolus dose)
Study: 1300059
Drug: Urapidil 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil 12.5 mg
Study: 23642785
Drug: Monthly bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly bevacizumab
Study: 31539373
Drug: Vignette portraying
Normalized name: Ultra Violette Mini Mates Duo Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vignette portraying effectively treated mental illness or treatment followed by subsequent relapse
Study: 22415477
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks) with chemotherapy
Study: 22415477
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (placebo)
Study: 16303936
Drug: linoleic acid
Normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: linoleic acid (LA; 112 mg) and gamma‐linolenic acid (GLA; 15 mg) administered twice daily for 1 month
Study: 16303936
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily for 1 month
Study: 11575865
Drug: Nimodipine 60
Normalized name: nimodipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 60 mg four times daily (240 mg/d)
Study: 11575865
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg four times daily (120 mg/d)
Study: 8349366
Drug: Heparin exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin exercise treatment (5000 IU intravenous dose, treadmill exercise 20 times for 2-3 weeks)
Study: 3329125
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 2550 mg/day
Study: 19810125
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemoradiotherapy (CCRT)
Study: 30293208
Drug: Synbiotic supplementation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic supplementation (15 g prebiotics and 5 g probiotics containing Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum) for 12 weeks
Study: 30293208
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (5 g probiotics and 15 g maltodextrin) for 12 weeks
Study: 30293208
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g maltodextrin) for 12 weeks
Study: 27487193
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate 18 mg (with potential increases up to 72 mg/d)
Study: 15152897
Drug: zopiclone 5
Normalized name: zopiclone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zopiclone 5 mg
Study: 25617762
Drug: zopiclone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: zopiclone 10 mg
Study: 25617762
Drug: alcohol 50
Normalized name: nicotinyl alcohol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcohol 50 g
Study: 23896972
Drug: Bone-marrow derived
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow derived cell therapy (BMC) with a cell number above the median (324 × 10^6)
Study: 23896972
Drug: Bone-marrow derived
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow derived cell therapy (BMC) with a cell number below the median
Study: 23896972
Drug: Bone-marrow derived
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow derived cell therapy (BMC) without microvascular obstruction (MO)
Study: 23896972
Drug: Bone-marrow derived
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow derived cell therapy (BMC)
Study: 21521847
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (800 IU daily for 96 weeks)
Study: 21521847
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg daily for 96 weeks)
Study: 16977654
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (40,000 U once weekly for < or = 16 weeks)
Study: 16977654
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (delayed treatment until hemoglobin < 9 g/dL)
Study: 10917932
Drug: Procyanidin-rich chocolate
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procyanidin-rich chocolate (5.3 mg total procyanidin/g, 1.3 mg/g (‐)‐epicatechin)
Study: 28404091
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (25 mg)
Study: 24385121
Drug: 5-aminolevulonic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolevulonic acid (ALA) photodynamic therapy (PDT), two treatments, 2 weeks apart
Study: 24385121
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group observed without treatment
Study: 9397291
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist treatment
Study: 8394193
Drug: felodipine-ER (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine-ER (5 to 20 mg once daily)
Study: 26604731
Drug: Erdosteine (ER)
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine (ER) 900 mg daily
Study: 21870121
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g ALC twice a day for 90 days
Study: 10971236
Drug: Mesalazine foam
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalazine foam enema (2 g per day)
Study: 1799929
Drug: Bisoprolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (various doses)
Study: 1799929
Drug: Enalapril and
Normalized name: enalapril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril and hydrochlorothiazide combination
Study: 6381336
Drug: Chlorimipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (50 mg/day) + L-5-HTP (300 mg/day)
Study: 6381336
Drug: Chlorimipramine +
Normalized name: Chlorimipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorimipramine + L-5-HTP
Study: 19682769
Drug: Topical bexarotene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bexarotene 1% gel applied twice daily for 6 months
Study: 17577801
Drug: Bupropion (BUP)
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion (BUP) with standard cognitive-behavioral smoking cessation treatment (ST)
Study: 17577801
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for depression (CBTD) with BUP
Study: 17577801
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for depression (CBTD) with placebo (PLAC)
Study: 17577801
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) plus placebo (PLAC)
Study: 9650013
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg t.i.d. and sodium selenite (Se) 500 micrograms per day for 24 weeks (group A)
Study: 30617431
Drug: Life review
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life review therapy combined with memory specificity training (LRT-MST)
Study: 28065679
Drug: BDP/FF DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF DPI 200/12 μg
Study: 28065679
Drug: BDP/FF DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF DPI 800/48 μg
Study: 28065679
Drug: BDP/FF pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF pMDI 200/12 μg
Study: 28065679
Drug: BDP/FF pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF pMDI 800/48 μg
Study: 21507074
Drug: Low-frequency ultrasound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency ultrasound (US) at 36 kHz for 5 min, dosage from 1.57 to 3.50 W/cm(2)
Study: 17628185
Drug: Vitamin E-based
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E-based compounds
Study: 15530579
Drug: Computerized pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized pill bottles
Study: 2195580
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg in decaffeinated coffee)
Study: 28657933
Drug: Glucocorticoid low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid low dose (≤9 mg·kg prednisone)
Study: 28657933
Drug: Glucocorticoid high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid high dose (>9 mg·kg prednisone)
Study: 24461664
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg once a week for up to 24 months)
Study: 21723353
Drug: Different doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses of IXIARO
Study: 15631874
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (17.5 mg)
Study: 15631874
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg/day, 5 days weekly for 6 months, 3 days weekly at month 7 and 1 day/week at month 8)
Study: 15631874
Drug: Both nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both nicotine and fluoxetine
Study: 11334145
Drug: LR‐3280 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR‐3280 (doses from 1 to 24 mg) administered into target vessel through a guiding catheter
Study: 9327151
Drug: Doxorubicin 10
Normalized name: DOXOrubicin 10 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 10 mg/m2 every 2 weeks with bleomycin 10 U/m2 and vincristine 1.4 mg/m2, zidovudine 100 mg five times daily, and rhGM-CSF 5 micrograms/kg/day
Study: 9327151
Drug: rhGM-CSF at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF at doses of 2.5 to 5 micrograms/kg
Study: 9327151
Drug: Doxorubicin 20
Normalized name: DOXOrubicin 20 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 20 mg/m2
Study: 2576359
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride (10 mg)
Study: 2576359
Drug: Theophylline (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (7 mg/kg b.w.)
Study: 2576359
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride (10 mg) and Theophylline (7 mg/kg b.w.) combined
Study: 1105483
Drug: Prazosin 5
Normalized name: prazosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 5 mg three or four times a day
Study: 1105483
Drug: Prazosin in
Normalized name: Product containing prazosin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin in combination with polythiazide
Study: 19424085
Drug: Galantamine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8 mg/day for 4 weeks then 16 mg/day for another 4 weeks)
Study: 9230143
Drug: Controlled-release niacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release niacin
Study: 8477561
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg/day for 5 days)
Study: 28468642
Drug: Short cognitive
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cognitive behavioural therapy (CBT)-based treatment by mental health nurse practitioners (MHNPs) in addition to usual GP care
Study: 28468642
Drug: Short cognitive
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short cognitive behavioural therapy (CBT)-based treatment by MHNPs
Study: 21978713
Drug: Oral desensitisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitisation with cow's milk
Study: 21978713
Drug: Oral desensitisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitisation with hen's egg
Study: 21978713
Drug: Oral desensitisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitisation with cow's milk and hen's egg
Study: 21978713
Drug: Oral desensitisation
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitisation with raw hen's egg
Study: 16612399
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of antioxidant compounds, such as acetylcysteine and ascorbic acid
Study: 8612383
Drug: Buccal mode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mode inhalation technique
Study: 8612383
Drug: Pulmonary mode
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary mode inhalation technique
Study: 6141436
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy every 8 weeks for 2 years
Study: 30238584
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment plus 308 nm excimer lamp
Study: 30238584
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment plus 308 nm excimer lamp plus fractional CO2 laser
Study: 25119339
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (0 mg/kg/d)
Study: 25119339
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (1 mg/kg/d)
Study: 25119339
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (2 mg/kg/d)
Study: 20488346
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 10 sessions
Study: 18833859
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Intact teeth (no preparation)
Study: 11838889
Drug: Food service
Normalized name: BENZALKONIUM CHLORIDE 0.13 in 1 mL TOPICAL SOAP [RD Food Service DBA Restaurant Depot]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Food service intervention (training workshops for cooks and monthly site visits)
Study: 10367619
Drug: Cytokine production
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine production of G-CSF
Study: 1981698
Drug: 0.50 mg
Normalized name: EVEROLIMUS 0.50 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg etizolam
Study: 1981698
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg etizolam
Study: 28414728
Drug: Injection-naïve children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-naïve children with clown-care
Study: 19961603
Drug: Physiotherapy, corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy, corticosteroid injection, and naproxen
Study: 19961603
Drug: Physiotherapy, placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy, placebo injection, and naproxen
Study: 19961603
Drug: Wait and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait and see treatment with naproxen alone
Study: 15128682
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with omeprazole and serological H.pylori testing
Study: 9566670
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (average 6.0+/−0.2 mg daily)
Study: 8313822
Drug: Erythromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (150 mg)
Study: 24751173
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (coaches who did not receive coach education sessions)
Study: 23517933
Drug: Adalimumab induction
Normalized name: adalimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab induction (160/80 mg)
Study: 23517933
Drug: Adalimumab maintenance
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab maintenance (40 mg every-other-week)
Study: 22319691
Drug: Steroid-antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-antibiotic
Study: 18466276
Drug: Microwave disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave disinfection + topical miconazole (three times per day for 30 days)
Study: 18466276
Drug: Topical miconazole
Normalized name: miconazole Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical miconazole (three times per day for 30 days)
Study: 10960945
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2 i.v. 3-hour infusion on day 1) + Carboplatin (AUC 6)
Study: 10960945
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2 i.v. 3-hour infusion on day 1) + Gemcitabine (1,000 mg/m2 on days 1 and 8)
Study: 2419693
Drug: Pafenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafenolol 50 mg once daily
Study: 2419693
Drug: Pafenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafenolol 100 mg once daily
Study: 27444425
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (Motivational Enhancement Therapy and Prolonged Exposure delivered concurrently)
Study: 27444425
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (Motivational Enhancement Therapy and Prolonged Exposure delivered sequentially)
Study: 25261164
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (25 μg/d)
Study: 31365099
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (10 μg/d)
Study: 20543019
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy plus proprioceptive neuromuscular facilitation plus neuromobilization (Experimental group 2)
Study: 20543019
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy plus proprioceptive neuromuscular facilitation (Experimental group 1)
Study: 20543019
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (Control group)
Study: 19115912
Drug: Acetazolamide 250
Normalized name: acetazolamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide 250 mg/day (125 mg bid)
Study: 12939216
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg on alternate days)
Study: 6383614
Drug: Long-term drug
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term drug therapy (cyclophosphamide)
Study: 6383614
Drug: Short-term drug
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term drug therapy (cyclophosphamide)